SCHEMBL31368435

SCHEMBL31368435

NC(=O)c1cncc(S(=O)(=O)CCO)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.42
RAF1 P04049 1/20 0.38
PKMYT1 Q99640 1/20 0.38
MKNK1 Q9BUB5 3/20 0.36
MKNK2 Q9HBH9 3/20 0.36
SIRT2 Q8IXJ6 6/20 0.36
SIRT1 Q96EB6 6/20 0.36
SIRT3 Q9NTG7 6/20 0.36
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
SARM1 Q6SZW1 1/20 0.36
SIRT6 Q8N6T7 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
SIRT4 Q9Y6E7 1/20 0.36
APLNR P35414 1/20 0.35
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
PLK4 O00444 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3121621 0.83 FLT4 (0.44) RAF1PKMYT1MKNK1MKNK2SIRT2
SCHEMBL3129445 0.76 RAF1 (0.44) RAF1PKMYT1MKNK1MKNK2SIRT2
SCHEMBL2853143 0.75 GAA (0.50) CA2
SCHEMBL4636646 0.72 MAPT (0.43) RAF1PKMYT1MKNK1MKNK2SIRT2
SCHEMBL2841794 0.72 SIRT2 (0.54) RAF1PKMYT1MKNK1MKNK2SIRT2
SCHEMBL7397540 0.71 CYP2C9 (0.47) CA2RAF1MKNK1MKNK2
SCHEMBL31368501 0.71 CA2 (0.36) CA2RAF1PKMYT1MKNK1MKNK2
SCHEMBL23094111 0.69 FLT4 (0.38) APLNRPLK4AURKAROCK2CHEK2
SCHEMBL4304457 0.69 CA2 (0.42) CA2CYP11B2DYRK1A
SCHEMBL4637536 0.69 MEN1 (0.46) RAF1PKMYT1MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP claimed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO claimed
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed